Current understanding of HSP90 as a novel therapeutic target: An emerging approach for the treatment of Cancer

Current Pharmaceutical Design

Volumn 22, Issue 20, 2016, Pages 2947-2959

  Haque, Absarul ^a   Alam, Qamre ^a   Alam, Mohammad Zubair ^a   Azhar, Esam I ^a   Sait, Khalid Hussain Wali ^b   Anfinan, Nisrin ^b   Mushtaq, Gohar ^a   Kamal, Mohammad Amjad ^a,c,d   Rasool, Mahmood ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^c Enzymoics   (Australia)

^d Global Community Educational Foundation   (Australia)

Author keywords

17 AAG; 17 DMG; Cancer; Drug; Heat shock protein; HSP90; IP104

Indexed keywords

ALVESPIMYCIN; BORTEZOMIB; CISPLATIN; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; RADICICOL; RETASPIMYCIN; TANESPIMYCIN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ORGANELLE; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 84973620879     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160325152200     Document Type: Article

References (173)

1. Ritossa F. A new puffing pattern induced by temperature shock and DNP in Drosophila. Cell Mol Life Sci 1962; 18: 571-3.
2. Tissieres A, Mitchell HK, Tracy UM. Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs. J Mol Biol 1974; 84: 389-98.
3. Gao H, Wang Y, Liu X, et al. Global transcriptome analysis of the heat shock response of Shewanella oneidensis. J Bacteriol 2004, 186: 7796-803.
4. Young JC, Agashe VR, Siegers K et al. Pathways of chaperonemediated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004; 5: 781-91.
5. Lindquist S. The heat-shock response. Annu Rev Biochem 1986; 55: 1151-91.
6. Jolly C, Morimoto RI. Role of the heat shock protein response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 92: 1564-72.
7. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 381: 571-9.
8. Jego G, Hazoume A, Seigneuric R, et al. Targeting heat shock proteins in cancer. Cancer Lett 2013; 332: 275-85.
9. Calderwood SK, Khaleque MA, Sawyer DB et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006; 31: 164-72.
10. Lanneau DA, de Thonel S, Maurel C, et al. Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27. Prion 2007; 1: 53-60.
11. Tannock I. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998; 351: 9-16.
12. O'Connell MJ, Laurie JA, Kahn M, et al. prospectively randomized trial of postoperative adjuvant chemotherapy in patients with highrisk colon cancer. J Clin Oncol 1998; 16: 295-300.
13. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 91: 1281-7.
14. Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anticancer activities. Cancer Lett 2010; 290: 24-35.
15. Kim LS, Kim JH. Heat shock protein as molecular targets for breast cancer therapeutics. J Breast Cancer 2011; 14: 167-74.
16. Sarto C, Binz PA, Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000; 21: 1218-26.
17. Morimoto RI, Kline MP, Bimston DN, et al. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 1997; 32: 17-29.
18. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295: 1852-8.
19. Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-260.
20. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003; 362: 469-76.
21. Voellmy R. Feedback regulation of the heat shock response. Handb Exp Pharmacol 2006; 172: 43-68.
22. Li Z, Menoret, Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002; 14: 45-51.
23. Srivastava PK. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2000; 22: 185-94.
24. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
25. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003; 22: 9041-7.
26. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007; 32: 517-30.
27. Schulz R, Marchenko ND, Holembowski L, et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 2012; 13: 275-89.
28. Becker B, Multhoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004; 13: 27-32.
29. Elmore LW, Forsythe R, Forsythe H, et al. Overexpression of telomerase- associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas. Oncol Rep 2008; 20: 613-7.
30. Diehl MC, Idowu MO, Kimmelshue K, et al. Elevated expression of nuclear Hsp90 in invasive breast tumors. Cancer Biol Ther 2009; 8: 1952-61.
31. Milicevic Z, Bogojevic D, Mihailovic M, et al. Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression. Int J Oncol 2008; 32: 1169-78.
32. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439-53.
33. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003; 37: 198-207.
34. Abe M, Manola JB, Oh WK, et al. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer 2004; 3: 49-53.
35. Hwang TS, Han HS, Choi HK, et al. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol 2003; 18: 690-700.
36. Lazaris ACH, Chatzigianni EB, Panoussopoulos D, et al. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 1997; 43: 43-51.
37. Małusecka E, Zborek A, Krzyzowska-Gruca S, et al. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res 2001; 21: 1015-21.
38. Athanassiadou P, Petrakakou E, Sakelariou V, et al. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours. Eur J Cancer Prev 1998; 7: 225-31.
39. Ralhan R, Kaur J. Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1995; 1: 1217-22.
40. Kaddurah-Daouk R, Greene JM, Baldwin AS Jr, et al. Activation and repression of mammalian gene expression by the c-myc protein. Genes Dev 1987; 1: 347-57.
41. Taira T, Sawai M, Ikeda M, et al. Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y. J Biol Chem 1999; 274: 24270-9.
42. Tsutsumi-Ishii Y, Tadokoro K, Hanaoka F, et al. Response of heat shock element within the human Hsp70 promoter to mutated p53 genes. Cell Growth Differ 1995; 6: 1-8.
43. Simon MC, Fisch TM, Benecke BJ, et al. Definition of multiple, functionally distinct TATA elements, one of which is a target in the hsp70 promoter for E1A regulation. Cell 1988; 52: 723-9.
44. Williams GT, McClanahan TK, Morimoto RI. E1a transactivation of the human Hsp70 promoter is mediated through the basal transcriptional complex. Mol Cell Biol 1989; 9: 2574-87.
45. Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004; 200: 425-35.
46. Komarova EY, Afanasyeva EA, Bulatova MM, et al. Dwnstream caspases are novel targets for the antiapoptotic activity of the molecular chaperone hsp70. Cell Stress Chaperones 2004; 9: 265-75.
47. Li CY, Lee JS, Ko YG, et al. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem 2000; 275: 25665-71.
48. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469-75.
49. Mosser DD, Caron AW, Bourget L, et al. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000; 20: 7146-59.
50. Song J, Takeda M, Morimoto RI. Bag1-Hsp70 mediates a physiological stress signaling pathway that regulates Raf-1/ERK and cell growth. Natl Cell Biol 2001; 3: 276-82.
51. Arts HJ, Hollema H, Lemstra W, et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer 1999; 84: 234-8.
52. Malusecka E, Zborek A, Krzyzowska-Gruca S, et al. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res 2001; 21: 1015-21.
53. Garrido C, Fromentin A, Bonnotte B, et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res 1998; 58: 5495-9.
54. Lemieux P, Oesterreich S, Lawrence JA, et al. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 1997; 17: 113-23.
55. Choi DH, Ha JS, Lee WH, et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 2007; 58: 1649-56.
56. Acunzo J, Andrieu C, Baylot V, et al. Hsp27 as a Therapeutic Target in Cancers. Curr Drug Targets 2014; 15: 423-31.
57. Haynes CM, Ron D. The mitochondrial UPR - protecting organelle protein homeostasis. J Cell Sci 2010; 123: 3849-55.
58. Perisic O, Xiao H, Lis JT. Stable binding of Drosophila heat shock factor to head-to-head and tail-to-tail repeats of a conserved 5 bp recognition unit. Cell 1989; 59: 797-806.
59. Shi Y, Mosser DD, Morimoto RI. Molecular chaperones as HSF1- specific transcriptional repressors. Genes Develop 1998; 12: 654- 66.
60. Stetler RA, Gan Y, Zhang W, et al. Heat Shock Proteins: Cellular and molecular mechanisms in the CNS. Prog Neurobiol 2010; 92: 184-11.
61. Verghese J, Abrams J, Wang Y, et al. Biology of the heat shock response and protein chaperones: budding yeast (Saccharomyces cerevisiae) as a model system. Microbiol Mol Biol Rev 2012; 76: 115-58.
62. Munro S, Pelham HR. An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 1986; 46: 291-300.
63. Leustek T, Dalie B, Amir-Shapira D, et al. A member of the Hsp70 family is localized in mitochondria and resembles Escherichia coli DnaK. Proc Natl Acad Sci USA 1989; 86: 7805-8.
64. Mizzen LA, Chang C, Garrels JI, et al. Identification, characterization, and purification of two mammalian stress proteins present in mitochondria, grp 75, a member of the hsp 70 family and hsp 58, a homolog of the bacterial groEL protein. J Biol Chem 1989; 264: 20664-75.
65. Sadler I, Chiang A, Kurihara T, et al. A yeast gene important for protein assembly into the endoplasmic reticulum and the nucleus has homology to DnaJ, an Escherichia coli heat shock protein. J Cell Biol 1989; 109: 2665-75.
66. Syken J, De-Medina T, Münger K. TID1, a human homolog of the Drosophila tumor suppressor l(2)tid, encodes two mitochondrial modulators of apoptosis with opposing functions. Proc Natl Acad Sci USA 1999; 96: 8499-504.
67. Yu M, Haslam RH, Haslam DB. HEDJ, an Hsp40 co-chaperone localized to the endoplasmic reticulum of human cells. J Biol Chem 2000; 275: 24984-92.
68. Kurisu J, Honma A, Miyajima H, et al. MDG1/ERdj4, an ERresident DnaJ family member, suppresses cell death induced by ER stress. Genes Cells Devoted Mol Cell Mech 2003; 8: 189-202.
69. Cunnea PM, Miranda-Vizuete A, Bertoli G, et al. ERdj5, an endoplasmic reticulum (ER)-resident protein containing DNAJ and thioredoxin domains, is expressed in secretory cells or following ER stress. J Biol Chem 2003; 278: 1059-66.
70. Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol 2007; 14: 1204-6.
71. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
72. Workman P, Burrows F, Neckers L, et al. Drugging the Cancer Chaperone HSP90. Ann NY Acad Sci 2007; 1113: 202-16.
73. Dollins DE, Warren JJ, Immormino RM, et al. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 2007; 28: 41-56.
74. Felts SJ, Owen BAL, Nguyen P, et al. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000; 275: 3305-12.
75. Schulte TW, Akinaga S, Murakata T, et al. Interaction of radicicol with members of the heat shock Protein 90 family of molecular chaperones. Mol Endocrinol 1999; 13: 1435-48.
76. Pridgeon JW, Olzmann JA, Chin L-S, et al. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007; 5: e172.
77. Masuda Y, Shima G, Aiuchi T, et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by β-hydroxyisovalerylshikonin. J Biol Chem 2004; 279: 42503-15.
78. Lepock JR, Frey HE, Heynen ML, et al. The nuclear matrix is a thermolabile cellular structure. Cell Stress Chaperones 2001; 6: 136-47.
79. Michels AA, Nguyen VT, Konings AWT, et al. Thermostability of a nuclear-targeted luciferase expressed in mammalian cells. Eur J Biochem 1995; 234: 382-9.
80. Lee YJ, Borrelli MJ, Corry PM. Mechanism(s) of heat killing: Accumulation of nascent polypeptides in the nucleus? Biochem Biophys Res Comm 1991; 176: 1525-31.
81. Ohtsuka K, Laszlo A. The relationship between hsp 70 localization and heat resistance. Exp Cell Res 1992; 202: 507-18.
82. Nollen EAA, Brunsting JF, Roelofsen H, et al. In vivo chaperone activity of heat shock protein 70 and thermotolerance. Mol Cell Biol 1999; 19: 2069-79.
83. Arrigo AP, Landry J. Expression and function of the low-molecular weight heat shock proteins. In: Morimoto RI, Tissieres A, Georgopoulos C. Eds. The Biology of the Heat Shock Proteins and Molecular chaperones. Cold Spring Harbor: Cold Spring Harbor Laboratory Press New York 1994; pp. 335-373.
84. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-66.
85. Melcher A, Todryk S, Hardwick N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581-7.
86. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998; 396: 336-42.
87. Yamano T, Murata S, Shimbara N, et al. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J Exp Med 2002; 196: 185-96.
88. Ullrich SJ, Robinson EA, Law LW, et al. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci USA 1986; 83: 3121-5.
89. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994; 152: 5398-403.
90. Neckers L. Hsp90 inhbitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55-61.
91. Crevel G, Bates H, Huikeshoven H, et al. The Drosophila Dpit47 protein is a nuclear Hsp90 co-chaperone that interacts with DNA polymerase alpha. J Cell Sci 2001; 114: 2015-25.
92. Hickey E, Brandon SE, Sadis S et al. Molecular cloning of sequences encoding the human heat-shock proteins and their expression during hyperthermia. Gene 1986; 43: 147-154.
93. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol Cancer Ther 2004; 3: 1021-30.
94. Grammatikakis N, Vultur A, Ramana CV et al. The role of Hsp90n, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 2002; 277: 8312-20.
95. Dutta R, Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 2000; 25: 24-8.
96. Maruya M, Sameshima M, Nemoto T, et al. Monomer arrangement in Hsp90 dimer as determined by decoration with N and C-terminal region soecific antibodies. J Mol Biol 1999; 285: 903-7.
97. Nemoto T, Ohara-Nemoto Y, Ota M, et al. Mechanism of dimer formation of the 90-kDa heat shock protein. Eur J Biochem 1995; 2331-8.
98. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006; 75: 271-94.
99. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008; 283: 18473-7.
100. Prodromou C, Roe SM, O'Brien R et al. Identification and structural characterization of the ATP/ADPbinding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65.
101. Fang L, Ricketson D, Getubig L, et al. Unliganded and hormonebound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain. Proc Natl Acad Sci USA 2006; 103: 18487-92.
102. Southworth DRA. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. Mol Cell 2008; 32: 631-40.
103. Mickler M, Hessling M, Ratzke C, et al. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nat Struct Mol Biol 2009; 16: 281-6.
104. Hessling M, Richter K, Buchner J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat Struct Mol biol 2009; 16: 287-93.
105. Wayne N, Bolon DN. Dimerization of Hsp90 is required for in vivo function. Design and analysis of monomers and dimers. J Biol Chem 2007; 282: 35386-95.
106. Johnson VA, Singh EK, Nazarova LA.et al. Macrocyclic inhibitors of Hsp90. Curr Top Med Chem 2010; 23: 1380-402.
107. Senju M, Sueoka N, Sato A, et al. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 2006; 132: 150-8.
108. Sreedhar AS, Kalmar E, Csermely P, et al. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004; 562: 11- 5.
109. Shaknovich R, Shue G., Kohtz DS. Conformational activation of a basic helix-loop-helix protein (MyoD1) by the C-terminal region of murine HSP90 (HSP84). Mol Cell Biol 1992; 12: 5059-68.
110. Nathan DF, Lindquist S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol Cell Biol 1995; 15: 3917-25.
111. Wartmann M, Davis RJ. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J Biol Chem 1994; 269: 6695-701.
112. Hartson SD, Matts RL. Association of Hsp90 with cellular Srcfamily kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry 1994; 33: 8912-20.
113. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318- 21.
114. Ozes ON, Mayo LD, Gustin JA, et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-5.
115. Lewis J, Devin A, Miller A, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptorinteracting protein (RIP), and blockage of tumor necrosis factorinduced nuclear factor-αB activation. J Biol Chem 2000; 275: 10519-26.
116. Zhang Y, Wang JS, Chen LL, et al. Repression of hsp90beta gene by p53 in UV irradiation-induced apoptosis of Jurkat cells. J Biol Chem 2004; 279: 42545-51.
117. Hur E, Kim HH, Choi SM, et al. Reduction of hypoxiainduced transcription through the repression of hypoxia-inducible factor- 1_/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 2002; 62: 975-82.
118. Munster PN, Marchion DC, Basso AD, et al. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3- kinase- AKT-dependent pathway. Cancer Res 2002; 62: 3132-7.
119. Bando Y, Katayama T, Kasai K, et al. GRP94 (94 kDa glucoseregulated protein) suppresses ischemic neuronal cell death against ischemia/reperfusion injury. Eur J Neurosci 2003; 18: 829-40.
120. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004; 206: 149-57.
121. Workman P, Burrows F, Neckers L, et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007; 1113: 202-16.
122. Thomas X, Campos L, Le QH, et al. Heat shock proteins and acute leukemias. Hematology 2005; 10: 225-35.
123. Huang S, Ingber DE. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res 2000; 261: 91-103.
124. Xiao L, Lu X, Ruden DM. Effectiveness of hsp90 inhibitors as anticancer drugs. Mini Rev Med Chem 2000; 66: 1137-43.
125. Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anticancer activities. Cancer Lett 2010; 290: 24-35.
126. Ho N, Li A, Li S, et al. Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies. Pharmaceuticals 2012; 5: 779-801.
127. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res 2012; 18: 64-76.
128. McDonald E, Workman P, Jones K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem 2006; 6: 1091-107.
129. Li Y, Zhang D, Xu J, Shi J, et al. Discovery and development of natural heat shock protein 90 inhibitors in cancer treatment. Acta Pharm 2012; 2: 238-45.
130. Hwang M, Moretti L, Lu B. HSP90 inhibitors: multitargeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem 2009; 16: 3081- 92.
131. Ozgur A, Tutar Y. Heat shock protein 90 inhibitors in oncology. Curr Proteomics 2014; 11: 2-16.
132. Amolins MW, Blagg BS. Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev Med Chem 2009; 9: 140-52.
133. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005; 11: 1131-8.
134. Jhaveri K, Taldone T, Modi S, et al. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012; 1823: 742-55.
135. Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 2005; 1: 273-81.
136. Usmani SZ, Bona R, Li Z. 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 2009, 9: 654-64.
137. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr- Ablpositive human leukemic blasts. Cancer Res 2001; 61: 1799-804.
138. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
139. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007; 110: 2641- 9.
140. Ghalhar MG, Akbarzadeh A, Rahmati M, et al. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer. Asian Pacific J Cancer Prev 2014; 15: 7113-8.
141. Holzbeierlein JM, Windsperger A, Vielhauer G. Hsp90: a drug target? Curr Oncol Rep 2010; 12: 95-101.
142. Hertlein E, Amy J, Wagner et al. 17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010; 11: 45-53.
143. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI- 504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drug 2009: 18: 1375-83.
144. Patterson J, Palombella VJ, Fritz C, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2008; 61: 923-32.
145. Delmotte P, Delmotte-Plaquee J. A new antifungal substance of fungal origin. Nature 1953; 171: 344.
146. Pillay I, Nakano H, Sharma SV. Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from Src-transformed cells. Cell Growth Differ 1996; 7: 1487-99.
147. Hadden MK, Lubbers DJ, et al. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem 2006; 6: 1173-82.
148. Schulte TW, Akinaga S, Soga S, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998; 3: 100-8.
149. Soga S, Shiotsu Y, Akinaga S, et al. Development of radicicol analogues. Curr Cancer Drug Targets 2003; 3: 359-69.
150. Soga S, Kozawa T, Narumi H, et al. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway. J Biol Chem 1998; 273: 822-8.
151. Soga S, Leonard M, Neckers TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999; 59: 2931-8.
152. Abramson JS, Chen W, Juszczynski P, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of akt-dependent diffuse large B-cell lymphomas. Br J Haematol 2009; 144: 358-66.
153. Lazenby M, Hills R, Burnett AK, et al. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Res 2015; 39: 617- 24.
154. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolonecontaining Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Therap 2012; 11: 475-84.
155. Friedland JC, Smith DL, Sang J, et al. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs 2014; 32: 14-24.
156. Bao R, Lai C-J, Qu H, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009; 15: 4046-57.
157. Taldone T, Gozman A, Maharaj R, et al. Targeting Hsp90: smallmolecule inhibitors and their clinical development. Curr Opin Pharmacol 2008; 8: 370-4.
158. Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta 2012; 1823: 756-66.
159. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. New Eng J Med 1973; 288: 998-1006.
160. Coldman AJ, Goldie JH. Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treatment Rep 1985; 69: 1041-8.
161. Lu X, Xiao L, Wang L, et al. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem Pharmacol 2012; 83: 995-1004.
162. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17: 5132-9.
163. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double- strand breaks. Cancer Res 1988; 48: 4484-8.
164. Liao ZY, Zhang SH, Zhen YS. Synergistic effects of geldanamycin and antitumor drugs. Yao Xue Xue Bao = Acta Pharm Sinica. 2001; 36: 569-75.
165. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 2004; 65: 235-43.
166. Sano M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology 2001; 40: 947-53.
167. Roh JL, Kim EH, Park HB, et al. The Hsp90 inhibitor 17- (allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer. Cell Death Dis 2013; 4: e956.
168. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer (Tokyo, Japan). 2004; 11: 82-5.
169. André N, Meille C. Taxanes in paediatric oncology: and now? Cancer Treatment Reviews. 2006; 32: 65-73.
170. Solit DB, Basso AD, Olshen AB, et al. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63: 2139-44.
171. Münster PN, Basso A, Solit D, et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapyinduced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17- demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001; 7: 2228-36.
172. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092- 100.
173. Richardson PG, Badros AZ, Jagannath S, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010; 150: 428-37.